astrazeneca-sign

AZ’s hopes for Fasenra in COPD suffer terminal blow

pharmafile | May 30, 2018 | News story | Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical 

It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in trial results released earlier this month.

AstraZeneca has now released the results from the second trial into the area and they only confirm the company’s fears, the treatment is a dud for COPD.

The short press release simply states that the trial did not meet its primary endpoint of reducing exacerbations and, perhaps coming as no surprise, would not be pursuing a regulatory submission any time soon.

Advertisement

Dr Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options. We will now analyse the complete data sets from the Galathea and Terranova trials to further understand these results.”

The news will come as a relief to GSK, which has a rival treatment, in Nucala, already on the market and is seeking approval for the same indication that Fasenra will now miss out on, in COPD.

GSK’s results did not progress without a hitch, with one trial (Metrex) showing successful reduction of exacerbations while in another (Metreo) the treatment failed to achieve statistical significance.

The latest setback for AZ for its product could now see it lose further ground on the first-in-class leader, despite the advantages it holds in less frequent administration (eight weeks vs four week).

Ben Hargreaves

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

The Gateway to Local Adoption Series

Latest content